Our ability to take a long-term view on the prospects of the Danish healthcare firm was a crucial component of our decision to add it to the Henderson EuroTrust portfolio in 2017.
Patience pays off with Novo Nordisk
Divyaunsh Divatia
Divyaunsh (Div) Divatia is a Research Analyst at Janus Henderson Investors and serves on the Communications Sector Research Team. Before joining the firm in 2021, he was a vice president on the technology, media and telecom (TMT) team at Barclays Investment Bank from 2015 with a focus on cable, media and telecom sectors. Prior to
Multi-asset view: charting geopolitical risks
Portfolio Manager Oliver Blackbourn considers the potential ramifications of the conflict between Israel and Palestine at a geopolitical level, giving some insight into how markets have responded thus far.
Candice Sun
Referral di qualità: come alimentare la crescita del tuo business
Vuoi scoprire come sviluppare un processo per chiedere referrals e far crescere la tua attività?
Registrati all’ultima puntata di Microfoni Accesi; che si terrà Mercoledì 8 novembre alle 10:30 dove Bryan Powell, Senior Director Practice Management e Luca Poltronieri, Sales Manager, spiegheranno come espandere il proprio business attraverso processi, tecniche e strategie per attirare i clienti desiderati, replicando quindi i tuoi clienti migliori e rendere meno ansiogeno il processo legato alla “fatidica richiesta” attraverso ricerca, preparazione e pratica.
Global Perspectives: Demystifying securitized fixed income
Dissecting the securitized subset of the fixed income market and where we see the strongest opportunities ahead.
Matteo Ercole
Fixed maturity bond portfolios: Harvesting income opportunities
Harvesting the income opportunities within fixed income
Henderson High Income Trust plc – Insuring against the economic cycle
The uncertain economic environment presents challenges for investors in equities, as many sectors experience volatility. However, not all sectors behave in tandem and Henderson High Income has identified non-life insurers as one area that could buck the current market trend…
I&I therapies hit new milestones for patients and investors
The stocks of inflammation and immunology (I&I) focused companies have outperformed in 2023 and could continue to deliver in the years ahead.